Vitrolife Ab · OMXSTO:VITR

Vitrolife Ab — Q1 2021 Earnings Presentation

9 slides from Vitrolife Ab's earnings presentation, Apr 22, 2021

1. Slide 1: Interim report January – March 2021

   VITROLIFE AB (PUBL) Interim report January – March 2021 2021-04-22 Thomas Axelsson, CEO Mikael Engblom, CFO 1

2. Slide 2: Recovery and good profitability

   RECOVERY AND GOOD PROFITABILITY Q1:  Sales of 379 MSEK (334) equals +14% in SEK.  Sales increased by 20% in local currency.  EBITDA of 163 MSEK (116) corresponding to a margin of 43% (35). 2

3. Slide 3: Sales and growth per market region

   SALES AND GROWTH PER MARKET REGION SHARE OF VITROLIFE’S SALES 17% 42% 23% 18% ROLLING 12-MONTHS Q1 GROWTH RATE COMPARED TO LAST YEAR IN LOCAL CURRENCIES +7% +6% +50% +42% Total +20%* 3 * Whereof organic growth +20 percent

4. Slide 4: Current situation and short-term outlook

   CURRENT SITUATION AND SHORT-TERM OUTLOOK  The company estimates that the number of IVF treatments during the first quarter amounted to about as many as before the pandemic. However, large regional differences in recovery.  Increased vaccination supports the recovery of IVF markets and enables a re

5. Slide 5: Sales and growth per division

   SALES AND GROWTH PER DIVISION SEK millions, rolling 12m 1600 1400 125 136 91 1200 20 54 116 109 107 102 GENOMICS -7% 442 488 506 1000 398 352 446 391 363 397 TECHNOLOGY +36% 800 600 400 802 820 834 842 835 746 750 752 768 CONSUMABLES +15% 200 0 Quarterly growth, Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 local curr

6. Slide 6: Key financials Group Q1

   KEY FINANCIALS GROUP Q1 • Fluctuations in exchange rates negatively impacted EBITDA by 10 MSEK. • EBITDA margin positively impacted by a combination of high sales, favorable product mix and low expenses. • Cash and cash equivalents at the end of the period amounted to 1 118 MSEK. No financial loans.

7. Slide 7: Long-term outlook

   LONG-TERM OUTLOOK  Long-term market growth 5-10% in monetary terms  Expansion of sales  Broadening the product offering 7

8. Slide 8: Contact

   Contact: Thomas Axelsson, CEO, taxelsson@vitrolife.com, +46 31 721 80 01 Mikael Engblom, CFO, mengblom@vitrolife.com, +46 31 721 80 14

9. Slide 9: Disclaimer

   DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i

Vitrolife — Q1 2021 Earnings Presentation on 6ix